Trial Profile
A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs SHR-2554 (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Multiple myeloma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 15 Nov 2021 Planned number of patients changed from 120 to 231.
- 15 Nov 2021 Planned End Date changed from 1 Jun 2023 to 14 Aug 2023.